After 3–4 doses of cisplatin, the Veh/CIS group maintained significantly higher urinary KIM-1 levels (average 72-fold increase from baseline) than the other three treatment groups (p < 0.01; Fig. 4A). This evidence concerns the gene HAVCR1 and in situ carcinoma.